• James O Burton, Richard W Corbett, Philip A Kalra, Prashanth Vas, Vivian Yiu, Constantina Chrysochou, and Dimitrios Kirmizis.
• Department of Cardiovascular Sciences, 4488University of Leicester, Leicester LE1 7RH, UK.
• J R Soc Med. 2021 Jan 1; 114 (1): 303730-37.

AbstractHaemodialysis remains the most widely used treatment for patients with end-stage renal disease. Despite the progress that has occurred in the treatment of end-stage renal disease over the last six decades, there has been a failure to translate this into the desired clinical benefits, with morbidity and mortality rates among patients on haemodialysis remaining unacceptably high. Recently, however, there have been expectations that the significant advances that took place over the last few years may result in improved outcomes. New medications for the treatment of anaemia and secondary hyperparathyroidism, as well as novel trends in the areas of iron therapy, diabetes management and physical exercise are among the most important advances which, taken together, are changing the standards of care for patients on haemodialysis. The latest advances, of relevance not only to specialists in Renal Medicine but also to general practitioners caring for these patients, are reviewed in this collaborative paper.

27 keywords...

hide…